MK-8776 + Cytarabine
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelogenous Leukemia, Acute
Conditions
Myelogenous Leukemia, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Myelogenous Leukemia, Chronic, Aggressive Phase
Trial Timeline
Jul 29, 2009 → Jun 13, 2011
NCT ID
NCT00907517About MK-8776 + Cytarabine
MK-8776 + Cytarabine is a phase 1 stage product being developed by Merck for Myelogenous Leukemia, Acute. The current trial status is terminated. This product is registered under clinical trial identifier NCT00907517. Target conditions include Myelogenous Leukemia, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00907517 | Phase 1 | Terminated |
Competing Products
20 competing products in Myelogenous Leukemia, Acute
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bisantrene | Race Oncology | Phase 2 | 44 |
| Bisantrene + Fludarabine + Clofarabine | Race Oncology | Phase 2 | 44 |
| Milademetan + AZA + Milademetan | Daiichi Sankyo | Phase 1 | 33 |
| micafungin + posaconazole | Astellas Pharma | Approved | 85 |
| decitabine Induction Chemotherapy + Induction Chemotherapy | Eisai | Phase 2 | 52 |
| decitabine (5-aza-2'deoxycytidine) | Eisai | Phase 2 | 52 |
| Decitabine | Eisai | Phase 2 | 52 |
| Decitabine + Gemtuzumab ozogamicin | Eisai | Phase 2 | 52 |
| Ondansetron + Palonosetron | Eisai | Phase 2 | 52 |
| decitabine (5-aza-2'deoxycytidine) | Eisai | Phase 2 | 52 |
| Decitabine + Decitabine | Eisai | Phase 2 | 52 |
| Decitabine | Eisai | Phase 2/3 | 65 |
| KW-2449 | Kyowa Kirin | Phase 1 | 33 |
| KW-2449 | Kyowa Kirin | Phase 1 | 33 |
| flumatinib + imatinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| ABT-199 | AbbVie | Phase 2 | 52 |
| Posaconazole + ABT-199 + Decitabine + Azacitidine | AbbVie | Phase 1 | 33 |
| Venetoclax + Cytarabine | AbbVie | Phase 1/2 | 41 |
| AZD4877 | AstraZeneca | Phase 1 | 33 |
| MK0457 | Merck | Phase 1 | 33 |